Bioventus and MTF Biologics collaborate to develop placental tissue product for knee osteoarthritis

Bioventus, a global leader in orthobiologic solutions, has entered into a development collaboration agreement with MTF Biologics, the world’s largest tissue bank, to co-develop a next generation placental tissue product for the treatment of painful musculoskeletal conditions, with an initial focus on knee osteoarthritis (OA). Terms of the agreement were not disclosed.

Development of new orthobiologics offerings for osteoarthritis is a core focus for Bioventus and we are pleased to begin collaborating with MTF Biologics on a solution for knee OA that will offer symptom relief and potentially delay progression of the disease. We also expect to work together to develop additional uses and indications for this product as part of this program. There is a promising and growing body of preclinical and clinical evidence underscoring the potential of these preparations in supporting the body’s natural healing processes thanks to the inherent growth factors and regulatory molecules present in placental tissues.”

Tony Bihl, CEO, Bioventus

MTF Biologics is excited to begin working with Bioventus to bring this new solution to market. Through this relationship we expect to co-develop and deliver innovative biologic products for orthopaedics to patients and physicians.”

Joe Yaccarino, President and CEO, MTF Biologics

Source:

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post
You might also like... ×
Researchers report new regenerative medicine approach for treating osteoarthritis of the knee